Cadence Pharmaceuticals,'s quarterly market cap
declined
from Jun. 2013 (€472.59 Mil) to Sep. 2013 (€414.16 Mil) but then
increased
from Sep. 2013 (€414.16 Mil) to Dec. 2013 (€610.59 Mil).
Cadence Pharmaceuticals,'s annual market cap
stayed the same
from Dec. 2011 (€0.00 Mil) to Dec. 2012 (€0.00 Mil) but then
increased
from Dec. 2012 (€0.00 Mil) to Dec. 2013 (€610.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cadence Pharmaceuticals,'s Enterprise Value for Today is €887.38 Mil.
Cadence Pharmaceuticals, Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cadence Pharmaceuticals,'s Market Cap
For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadence Pharmaceuticals,'s Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Market Cap distribution charts can be found below:
* The bar in red indicates where Cadence Pharmaceuticals,'s Market Cap falls into.
Cadence Pharmaceuticals, Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cadence Pharmaceuticals,'s Market Cap for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadence Pharmaceuticals, (FRA:QEW) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cadence Pharmaceuticals, Market Cap Related Terms
Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cadence Pharmaceuticals, (FRA:QEW) Business Description
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:QEW has been successfully added to your 